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Abstract
Premature ventricular contractions (PVCs) and non-sustained ventricular tachycardia (NSVT) 
are frequently encountered and a marker of electrocardiomyopathy. In some instances, they 
increase the risk for sustained ventricular tachycardia, ventricular fibrillation, and sudden 
cardiac death. While often associated with a primary cardiomyopathy, they have also been 
known to cause tachycardia-induced cardiomyopathy in patients without preceding structural 
heart disease. Medical therapy including beta-blockers and class III anti-arrhythmic agents can 
be effective while implantable cardiac defibrillators (ICD) are indicated in certain patients. 
Radiofrequency ablation (RFA) is the preferred, definitive treatment in those patients that 
improve with anti-arrhythmic therapy, have tachycardia-induced cardiomyopathy, or have 
certain subtypes of PVCs/NSVT. We present a review of PVCs and NSVT coupled with case 
presentations  on RFA of fascicular ventricular tachycardia,  left-ventricular  outflow  tract 
ventricular tachycardia, and Purkinje arrhythmia leading to polymorphic ventricular tachycardia.
Key words: PVC, premature ventricular contractions, ventricular tachycardia, ablation, sudden 
death  
Introduction
Heart disease remains the leading cause of death in the United States [1].  Most of the 425,000 
deaths per year attributable to heart disease are due to sudden cardiac death (SCD) [1,2]. Despite 
a reduction in the incidence of SCD, primary prevention remains challenging, as SCD is the 
initial presentation of cardiac disease in many patients. Subtle clues to the presence of 
electrocardiomyopathy in these patients may have been absent or missed.                      
The presence of premature ventricular contractions (PVCs) and non-sustained ventricular 
tachycardia (NSVT) can be a marker of electrocardiomyopathy. While often considered benign, 
these types of ventricular ectopy can have negative consequences through an increased risk of 
SCD, underlying cardiomyopathy, or induction of cardiomyopathy. We discuss the relationship 
of PVCs and NSVT to SCD and cardiomyopathy, risk stratification strategies, and approaches to 
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management including common scenarios for ablation.                                                                 
Sudden Cardiac Death                                                                                                     
The estimated incidence of SCD in the United States is 300,000 deaths annually [2]. Commonly 
recognized   risk   factors   include   ischemic   heart   disease,   previous   cardiac   arrest,   and 
cardiomyopathy. Nearly 25% percent of deaths, however, occur in the general adult population 
with previously silent or unrecognized cardiac disease.  As the overall incidence of SCD in the 
Unites States is 0.1-0.2% per year, it would be challenging to apply a population-wide screening 
test or intervention. Much of the focus has been upon prevention and identification of ischemic 
heart disease, as this accounts for approximately 80% of SCD [2].                                        
The overall incidence of SCD appears to be decreasing [3]. Evidence in patients with out-of-
hospital cardiac arrest suggests that this reduction may be limited to patients with ischemic 
cardiac disease. The incidence of ventricular fibrillation outside the hospital arrest in patients 
from Rochester, MN with ischemic heart disease decreased while those with non-ischemic heart 
disease increased from 1991-2004 [4]. The gains may be attributable to improved primary and 
secondary prevention of coronary artery disease as well as advanced management strategies, 
including early reperfusion. Recent implementation of automated external defibrillators would 
be expected to reduce the incidence of SCD further in both groups. The use of therapeutic 
hypothermia improves outcomes for SCD in patients who have persistent coma after return of 
spontaneous circulation [4,5].                                                                                     
Since our currently identified risk factors fail to account for much of the population at risk for 
SCD and the incidence of SCD may be increasing in patients without ischemic heart disease, we 
must refocus our attention on this group, thus the need to identify new risk factors to capture a 
larger segment of those at risk.   Furthermore, we must recognize clues suggesting subtle 
electrocardiomyopathy.  
Definitions and Epidemiology                                                                                                 
PVCs are early depolarizations originating in the ventricle due to increased automaticity. NSVT 
occurs when three or more consecutive PVCs occur at a rate greater than 100 beats-per-minute 
(Figure 1). They may be monomorphic or polymorphic and are often present in patients 
presenting with nonspecific cardiac symptoms. While PVCs and NSVT are frequently seen in 
the general population and are sometimes considered clinically insignificant, they mark a 
population at increased risk for cardiac disease including SCD and cardiomyopathy. 
The incidence of PVCs and NSVT in the adult population varies. Ambulatory 24-hour ECG 
monitoring in male medical students identified PVCs in 50% of the cohort, but only 2% had 
more than 50 PVCs in 24 hours [6]. A Framingham Offspring Study in patients without known 
cardiac disease reported PVCs during exercise testing in 27% of patients. Those with PVCs had 
a statistically significant but small increased mortality hazards ratio of 1.71-1.86 [7]. Patients 
with heart disease have a higher incidence of complex or frequent arrhythmia [8]. Overall, 
ventricular ectopy appears to be a frequent finding with a small but statistically significant 
increased sudden cardiac death and mortality risk [9].
Presentation and Pathophysiology                                                                                   
The presentation of PVCs and NSVT varies and may include palpitations, chest pain, pre-
syncope, syncope, or heart failure. Dysrhythmias occur with increased automaticity, reentry, or 
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triggered automaticity.  PVCs arise from tissue with increased automaticity. This is influenced 
by   autonomic   tone,   ischemia/reperfusion,   systemic   abnormalities   such   as   electrolyte 
disturbances, and cardiotoxic factors [2]. Monomorphic VT typically occurs with reentry around 
a substrate or due to triggered automaticity as seen with right-ventricular outflow-tract 
tachycardia. Polymorphic VT is typically the result of increased automaticity.                       
There are three major concerns regarding the presence of PVCs and NSVT. The substrate often 
associated with monomorphic VT increases the risk for sustained VT. Another concern, 
particularly with increased automaticity and polymorphic VT, is that a ventricular beat may be 
coupled closely with the preceding QRS complex and produce ventricular fibrillation. In 
addition, frequent ventricular ectopy is known to adversely affect cardiac function itself, namely 
tachycardia-induced cardiomyopathy.
Figure 1:  Electrocardiogram demonstrating sinus rhythm with a five beat run of nonsustained ventricular 
tachycardia with left bundle branch block morphology (negative in V1).                                       
 
Relationship   to   Cardiomyopathy:   Primary   arrhythmia   or   primary   cardiomyopathy
It can be difficult to determine whether a primary cardiomyopathy is present resulting in 
ventricular  ectopy   or  a  primary  arrhythmia   causing  tachycardia-induced   cardiomyopathy 
(Figure 2) [9]. While supraventricular arrhythmias and ventricular tachycardias are recognized 
mediators of tachycardia-induced cardiomyopathy, PVCs have recently been shown to cause 
tachycardia-induced cardiomyopathy [10,11]. Differentiating a primary cardiomyopathy from 
tachycardia-induced cardiomyopathy is essential, as the latter may be reversible, particularly by 
radiofrequency ablation [12].
Certain factors are helpful in determining the primary disorder (Figure 3) [9]. Clues suggestive 
of a primary arrhythmia include 1) young, healthy patients without underlying cardiac disease; 
2) frequent ventricular ectopy (often >20,000 beats per day); and 3) one to two primary ectopy 
morphologies.   Ultimately,   improvement   in   ventricular   function   with   suppression   of   the 
arrhythmia via antiarrhythmic therapy or radiofrequency ablation (RFA) defines tachycardia-
induced cardiomyopathy.  
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Figure 2:  The upper portion of this figure depicts ectopy that can occur after myocardial injury has caused 
ventricular dysfunction.  Frequent PVC's may also cause ventricular remodeling as seen in the lower portion of the 
figure. VT = ventricular tachycardia; PVCs = premature ventricular contractions
Evaluation and Risk Stratification                                                                                           
An evaluation of patients with PVCs and NSVT should determine the extent of symptoms, 
evidence of underlying cardiomyopathy, the risk for tachycardia-induced cardiomyopathy, and 
the risk for sudden cardiac death. This begins with a focused history including associated 
symptoms, frequency, duration, triggers, family history, and risk factors for coronary artery 
disease. The physical exam should evaluate for evidence of systemic disease (such as connective 
tissue diseases, thyroid abnormalities, sarcoidosis, or amyloidosis).                                 
Routine   tests   include   a   resting   ECG,   24-hour   ambulatory   electrocardiography,   and   an 
echocardiogram. The ambulatory electrocardiogram can establish the frequency, duration, and 
morphology of ectopy. Early repolarization on electrocardiogram is prognostic of increased risk 
of death from cardiac causes [12]. The echocardiogram provides the left ventricular function and 
helps in the evaluation for underlying cardiomyopathy. Patients at risk for or with suspected 
coronary heart disease may require stress testing or coronary angiography. Additional diagnostic 
evaluation such as cardiac magnetic resonance imaging may be warranted depending on 
individual patient factors.                                                                                                         
Noninvasive and invasive methods of risk stratification for SCD are available. The most 
recognized risk factor is diminished left ventricular function as determined by the ejection 
fraction. This, however, fails to account for the majority of SCD cases [13].  Evaluation  for 
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underlying coronary heart disease can be helpful as this accounts for approximately 80% of 
SCD, although it has a low predictive power and is often non-specific [14]. Additional 
noninvasive   methods   are   available   including   ECG   markers,   assessment   of   baroreceptor 
sensitivity, and measurement of heart-rate variability. The ECG and SAECG may be used to 
evaluate QRS duration, for the presence of T-wave alternans, and for QT prolongation [13]. The 
presence of differing types of PVCs or NSVT increases the risk of polymorphic ventricular 
tachycardia   or   VF.   The   primary   invasive   method   for   risk   stratification   remains   an 
electrophysiology study. Using the gathered data, we must determine which patients to offer 
medical therapy, implantable cardiac defibrillators (ICD), or RFA.                                    
Figure 3: Characteristics of primary cardiomyopathy versus tachycardia-induced cardiomyopathy
Therapy: Implantable cardiac defibrillators                                                                                 
ICDs are recognized as the principal method of preventing sudden cardiac death in the highest-
risk population. The AVID study in patients with history of sudden cardiac arrest (secondary 
prevention) showed a reduction of overall mortality and SCD incidence with ICDs as compared 
with amiodarone [15]. MADIT II evaluated patients with left ventricular ejection fractions of 
less than 30% with history of previous myocardial infarction and showed a reduction in overall 
mortality with ICDs versus no ICD [16]. SCD-HeFT demonstrated the efficacy of ICDs in both 
ischemic and non-ischemic cardiomyopathy [17]. Unfortunately, the groups known to benefit 
from ICD therapy comprise a minority of the overall population at risk for sudden cardiac death. 
  
PVCs and NSVT increase the risk for sudden cardiac death. There is, however, little evidence 
evaluating the efficacy of ICDs in this population. The  MADIT I  study  showed a  survival 
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benefit with ICD therapy versus conventional therapy in patients with asymptomatic NSVT and 
symptomatic ischemic cardiomyopathy with an ejection fraction of less than 35% [18]. The 
DEFINITE study in patients with non-ischemic dilated cardiomyopathy, ejection fraction <36%, 
and NSVT or greater than 10 PVCs per hour demonstrated a reduction in overall mortality and 
sudden cardiac death with ICD therapy and conventional therapy versus conventional therapy 
alone [19]. Although PVCs or NSVT are components of the inclusion criteria in these studies, 
the study populations were limited to those with a diminished ejection fraction and thus were not 
inclusive of the major population at risk for SCD.                                            
Economic constraints and quality of life implications must be entertained when considering ICD 
therapy. A reduction in the incidence of sudden cardiac death may not equate to survival with 
meaningful quality of life [20]. Furthermore, the absolute risk reduction of SCD in the majority 
of patients with PVCs or NSVT may not warrant the cost of a $17,500 device [21]. In the 
absence of evidence to guide the use of ICDs in patients with PVCs or NSVT without a 
diminished ejection fraction, routine use of ICD therapy is not recommended. Further evaluation 
will be needed to determine the patients in this risk group that would benefit from ICD therapy. 
Presently, we must decide based on clinical presentation and electrocardiographic data which 
patients to offer medical therapy versus radiofrequency ablation.                                   
Therapy:   Medical                                                                                        
The goal of therapy for PVCs and NSVT is to 1) alleviate symptoms; 2) suppress ventricular 
tachyarrhythmias and PVCs; 3) prevent or reverse tachycardia-induced cardiomyopathy; and 4) 
decrease shocks in patients with ICDs. Lifestyle modifications such as reducing caffeine and 
alcohol intake can be recommended initially, although neither moderate use nor reduction in 
intake has a major effect on ventricular ectopy [16,17].                                                  
Beta-blockers can be considered for treatment of ventricular tachyarrhythmias. They decrease 
mortality in patients post-myocardial infarction [18] and in heart failure [19], at least partially 
due to a reduction in the incidence of SCD. Beta-blockers also reduce mortality in patients with 
ischemic cardiomyopathy with EF ≤ 40% and NSVT [22]. There is evidence showing a 
reduction in PVCs in the absence of a reduced EF [20,23]. In the setting of ventricular 
arrhythmia originating in the right ventricular outflow tract (RVOT), atenolol has been shown to 
modestly reduce PVCs with no statistically significant reduction in symptoms compared with 
placebo [21]. Beta-blockers are largely well-tolerated and, given a survival benefit in patients 
with ventricular arrhythmias, are a reasonable first-line drug but unlikely to provide definitive 
therapy.  
The role of antiarrhythmic drugs in the management of PVCs and NSVT is best assessed by 
evaluating   their   efficacies   versus   side-effect   profiles,   including   the   propensity   for   pro-
arrhythmic effects. Selection of antiarrhythmic drugs may be empiric, guided by the use of 
electrophysiology study with stimulation testing, or guided by ambulatory/exercise ECG 
monitoring   [24].                                                                                      
Arrhythmia suppression with class I antiarrhythmic drugs is not advised due to the results of the 
CAST trial [25]. Although effective in suppressing PVCs, the use of encainide and flecainide 
was associated with increased mortality in patients with history of myocardial infarction. This 
was attributed to proarrhythmic effects in the drug class, especially in patients with left-
ventricular dysfunction. Thus, class I antiarrhythmic agents are generally not recommended for 
suppression of PVCs or NSVT in patients with coronary disease.                                  
Class III antiarrhythmic drugs have been evaluated in patients at risk for SCD. The Amiodarone 
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Trials Meta-Analysis Investigators showed a 13% reduction in mortality and 29% reduction in 
SCD in patients with recent myocardial infarction or congestive heart failure treated with 
amiodarone versus placebo [26]. The SCD-HeFT trial, meanwhile, did not show a reduction in 
mortality with amiodarone in patients with New York Heart Association Class II or III heart 
failure with a left ventricular ejection fraction of less than 36% [17]. The discrepancy between 
these studies might be due to a higher mean LVEF in the former study.                                      
Another class III drug, dofetilide, has been studied in the setting of inducible sustained 
ventricular tachycardia. It appears to be as efficacious as sotalol and better tolerated, possibly 
due to less beta-blockade [27]. Dofetilide has a reasonable safety profile but little is known 
about the efficacy in PVCs and NSVT [28, 29].                                               
Given the pro-arrhythmic effects and adverse side effect profiles of most antiarrhythmic drugs, 
it is often impractical to use them for primary prevention of SCD. Nevertheless, in patients with 
structural  heart  disease  and symptomatic  or frequent  ventricular  ectopy,  amiodarone  or 
dofetilide could be used with caution. They may also be utilized short-term in the setting of 
suspected tachycardia-induced cardiomyopathy to evaluate for improvement of ejection fraction 
that might be sustained with radiofrequency ablation.                                         
Treatment:   Radiofrequency   ablation                                                              
RFA is an additional management option for PVCs and NSVT.  Determining the target site for 
ablation depends on the mechanism of the arrhythmia. Activation mapping is used with PVCs to 
identify the earliest activation point, representing the automatic tissue targeted for ablation. 
Alternatively, pace mapping can be utilized to find the paced site that matches spontaneous 
premature ventricular depolarization [22]. Common targets for RFA in primary arrhythmia 
disorders include: the right ventricular outflow tract [23] left ventricular outflow tract [30,31], 
papillary muscle [32] and the fascicles [33-35].                                                                         
RFA has been successful in alleviating symptomatic ventricular ectopy [23], reducing ICD 
shocks [36], and reversing tachycardia-induced cardiomyopathy [36]. There are, nevertheless, 
several associated risks that vary depending on the site of ablation and amount of energy 
delivered. These include bleeding, infection, cardiac perforation, coronary artery injury, and 
thromboembolism. Technological advances such as advanced electroanatomic mapping and 
intracardiac ultrasound [37] have made RFA safer and thus a viable option in certain patients 
with PVCs and NSVT. Further study will be needed to determine the long-term efficacy of RFA 
for ventricular ectopy.                                                                                                         
Management algorithm                                                                                       
Figure 4 is a proposed management algorithm. Determining the primary disorder is essential as 
arrhythmia suppression may reverse tachycardia-induced cardiomyopathy. Patients with a 
primary arrhythmia responding to medical therapy should be considered for RFA. It is also 
important to consider the patient's risk for SCD and the role for ICD.                       
Case 1: 19 year-old female with dyspnea on exertion                                                          
Monomorphic ectopic complexes strongly suggest a primary arrhythmic propensity as seen in 
the following illustrative case. A 19 year-old female presented with fatigue and dyspnea on 
exertion. Her electrocardiogram (Figure 5) demonstrated sinus rhythm with monomorphic 
PVCs. A Holter monitor recorded 19,000 PVCs in 24 hours.  
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Figure 4: Management algorithm for PVCs or NSVT
Figure 5:  Electrocardiogram demonstrating underlying sinus rhythm with frequent monomorphic PVCs.   The 
morphology of the PVCs suggests a LVOT focus. The first clue is the right bundle branch block morphology of the 
PVCs suggests left-sided origin. The second clue is that the PVCs are strongly positive in inferior leads (II, III, 
aVF) and strongly negative in aVR and aVL which suggests the origin is superior in the outflow tracts.
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She had a reduced left ventricular ejection fraction (32%) without evidence of obstructive 
coronary disease or anomalous anatomy. High dose beta-blocker therapy was poorly tolerated 
and ineffective at controlling her PVCs. Similarly, sotalol 120 mg by mouth twice daily caused 
fatigue and only minimal reduction in her PVCs.                                          
Since medical therapy was not effective for her, she was referred for an EP study. The 
morphology of her PVCs suggested an outflow tract origin given they were strongly positive in 
the inferior leads (II, III, aVF) and strongly negative in aVL and aVR.  The right bundle branch 
morphology (positive in V1) and S wave in lead I suggested a left-sided focus such as from the 
left ventricular outflow tract (LVOT) [38]. During the EP study, a lasso catheter was placed in 
the LVOT where the focus was localized based on activation at the Sinus of Valsalva (Figure 
6). She had symptomatic relief and resolution of her PVCs after ablation.
Figure 6: Intracardiac electrograms and EKG in a patient with an unusual supravalvar origin for PVCs.  EKG 
shows PVCs occurring in a begiminal pattern.  LS is a circumferential multielectrode catheter placed in the aortic 
route.  Note: small, spike-like signals that occur with or without related exit to the ventricle producing PVCs.  RVT 
= right ventricular; HRA = high right atrium; HBE1 and HBE2 = His bundle recording catheters; RVOT uni = right 
ventricular outflow tract unipola; AORT ablation = ablation catheter placed in the distal aortic outflow tract; CS = 
coronary   sinus.                                                                                
The outflow tracts are common sources of PVCs and have classic ECG patterns. The key 
electrocardiographic findings for an LVOT focus are illustrated above. An RVOT focus 
similarly has strongly inferior vector (positive II, III, aVF, negative in aVR and aVL) but with a 
left   bundle   branch   block   pattern   (positive   in   V1).   Arrhymothogenic   right   ventricular 
cardiomyopathy [39] is important to recognize when working up patients with outflow tract 
arrhythmias and appropriate imaging should be pursued.
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Case 2: 17 year-old hockey player with pre-syncope and palpitations                                    
Fascicular ventricular tachycardia [33] is a specific arrhythmia characterized by a relatively 
narrow QRS complex with a left bundle-branch block pattern that occurs in structurally normal 
hearts.   It   may   predispose   to   arrhythmic   events   and   possibly   tachycardia   induced 
cardiomyopathies. A 17 year-old hockey player presented with palpitations, presyncope and an 
abnormal electrocardiogram (Figure 7) demonstrating fascicular ventricular tachycardia that 
was confirmed by EP study (Figure 8) and was treated by ablation.                          
Figure 7: Typical electrocardiographic pattern of idiopathic left ventricular tachycardia (fascicular VT).  A typical 
right bundle morphology is noted in lead V1. Unlike outflow tract VT, however, leads AVl and AVr are both 
positive. A strong superior axis is noted, and the positive R wave dominates in lead one.                                      
These two cases examples demonstrate that primary arrhythmias may develop in patients who 
do not have a traditional cardiomyopathy. The astute clinician is mindful of the uncommon 
cardiomyopathies manifesting rhythm abnormalities.                                             
Case 3: 31 year-old with polymorphic VT                                                
Polymorphic ventricular tachycardia can, in specific circumstances, be treated by ablation. A 31 
year-old   female   collapsed   after   exercising   and   had   a   second   episode   while   shopping. 
Polymorphic   ventricular   tachycardia   /   ventricular   fibrillation   was   diagnosed,   and   her 
electrocardiogram had a borderline QT interval. She had no structural heart disease by 
echocardiogram and she did not provoke any evidence of arrhythmia during an exercise test. An 
ambulatory Holter monitor demonstrated repeated runs of minimally-symptomatic polymorphic 
VT   with   a   normal   QT   interval.   An   ICD   was   implanted   and   subsequent   interrogation 
demonstrated similar episodes with frequent detections and shocks. EP study found Purkinje 
potentials preceding PVCs (Figure 9) that induced polymorphic VT.  Using pacemapping, the 
fascicular focus was identified and ablated [32].
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Figure 8: Intracardiac tracings obtained when mapping a constant PVC that initiated ventricular fibrillation. Note 
the spike-like signals on the ablation electrodes (ABLD = ablation distal; ABLP = ablation proximal). In this 
instance, these signals represented the depolarization of the arrhythmogenic Purkinje fibers responsible for the 
arrhythmia. HBE = His bundle; RV = right ventricle; HRA = high right atrium; CS = coronary sinus  
Conclusion
PVCs and NSVT are frequently encountered in clinical practice. Their presence may increase the 
risk for more malignant dysrhythmias such as sustained VT or ventricular fibrillation that can 
cause sudden cardiac death. PVCs and NSVT can be associated with a reversible tachycardia-
induced cardiomyopathy or a primary cardiomyopathy. A focused evaluation and implementation 
of risk stratification strategies are helpful in treatment selection. RFA is effective in alleviating 
symptoms and reducing ICD shocks, especially in the setting of outflow tract or fascicular 
tachycardia. The presented cases highlight key points in the approach to RFA for PVCs and 
NSVT.
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Figure 9: EP tracing demonstrating the onset of ventricular fibrillation provoked by a PVC.  The arrow points to a 
Purkinje potential that precedes the PVC.  Note that the time interval from the Purkinje potential to the onset of the 
QRS varies likely because of different exit sites)                                                                                 
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